Collegium Pharmaceutical (NASDAQ:COLL) Trading Up 2.8% – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shot up 2.8% during trading on Wednesday . The stock traded as high as $30.00 and last traded at $29.97. 25,883 shares were traded during mid-day trading, a decline of 93% from the average session volume of 368,973 shares. The stock had previously closed at $29.14.

Analysts Set New Price Targets

COLL has been the subject of several analyst reports. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Stock Up 14.1 %

The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a fifty day simple moving average of $30.61 and a 200-day simple moving average of $34.05. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of 14.33 and a beta of 0.82.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently made changes to their positions in the company. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Foundry Partners LLC raised its position in shares of Collegium Pharmaceutical by 3.3% in the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after buying an additional 509 shares in the last quarter. CWM LLC boosted its stake in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the period. GAMMA Investing LLC grew its position in Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 792 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in Collegium Pharmaceutical by 4.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock worth $908,000 after acquiring an additional 983 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.